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Abstract
Background: Diabetes mellitus is a common co-existing disease in the critically ill. Diabetes mellitus may reduce
the risk of acute respiratory distress syndrome (ARDS), but data from previous studies are conflicting. The objective
of this study was to evaluate associations between pre-existing diabetes mellitus and ARDS in critically ill patients
with acute hypoxemic respiratory failure (AHRF).
Methods: An ancillary analysis of a global, multi-centre prospective observational study (LUNG SAFE) was
undertaken. LUNG SAFE evaluated all patients admitted to an intensive care unit (ICU) over a 4-week period, that
required mechanical ventilation and met AHRF criteria. Patients who had their AHRF fully explained by cardiac
failure were excluded. Important clinical characteristics were included in a stepwise selection approach (forward
and backward selection combined with a significance level of 0.05) to identify a set of independent variables
associated with having ARDS at any time, developing ARDS (defined as ARDS occurring after day 2 from meeting
AHRF criteria) and with hospital mortality. Furthermore, propensity score analysis was undertaken to account for the
differences in baseline characteristics between patients with and without diabetes mellitus, and the association
between diabetes mellitus and outcomes of interest was assessed on matched samples.
Results: Of the 4107 patients with AHRF included in this study, 3022 (73.6%) patients fulfilled ARDS criteria at
admission or developed ARDS during their ICU stay. Diabetes mellitus was a pre-existing co-morbidity in 913
patients (22.2% of patients with AHRF). In multivariable analysis, there was no association between diabetes mellitus
and having ARDS (OR 0.93 (0.78–1.11); p = 0.39), developing ARDS late (OR 0.79 (0.54–1.15); p = 0.22), or hospital
mortality in patients with ARDS (1.15 (0.93–1.42); p = 0.19). In a matched sample of patients, there was no
association between diabetes mellitus and outcomes of interest.
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Conclusions: In a large, global observational study of patients with AHRF, no association was found between
diabetes mellitus and having ARDS, developing ARDS, or outcomes from ARDS.
Trial registration: NCT02010073. Registered on 12 December 2013.
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Background
Acute hypoxemic respiratory failure (AHRF) is a com-
mon cause of admission to the intensive care unit (ICU).
Many patients with AHRF will meet criteria for acute re-
spiratory distress syndrome (ARDS), whilst those that do
not meet the criteria remain at risk of developing it.
ARDS remains a common condition in the critically ill
and is associated with high mortality [1]. The long-term
sequelae of ARDS are considerable, with substantive re-
ductions in long-term quality of life [2, 3].
Despite numerous clinical trials there remain few
therapeutic options for patients with ARDS [4]. Recent
studies have identified subphenotypes of ARDS, which
have a differential response to treatment [5]. The variety
of pre-disposing conditions and inciting events for
ARDS contributes to the heterogeneity of patients with
this condition. It has been hypothesised that this hetero-
geneity may explain why therapies that were effective in
exploratory studies were not shown to be effective in
phase III trials [4]. Targeting interventions to prevent
ARDS in patients at higher risk may prove more effect-
ive, and it is therefore necessary to identify those groups
of patients who have a higher risk of ARDS.
Diabetes mellitus is common [6], with 4.4% of the
world’s population anticipated to have a diagnosis by
2030 [7]. Observational data suggest that 40% of patients
admitted to ICUs have a pre-existing diagnosis of dia-
betes mellitus [8]. Diabetes mellitus may protect against
the development of ARDS. Whilst several studies indi-
cated that patients with diabetes mellitus are less likely
to develop ARDS [9–14], others did not demonstrate
any protective effect of diabetes mellitus [15, 16]. The ef-
fect of diabetes mellitus on the risk of mortality in critic-
ally ill patients is also unclear, with most [17–19], but
not all [16], data suggesting that diabetes mellitus is not
associated with an increased risk of mortality. No studies
have examined this relationship since the introduction
of the current Berlin definition of ARDS [20]. Therefore,
there remains a need to clarify and define any associa-
tions between diabetes mellitus and this syndrome. Any
potential association could have significant impact on a
clinician’s evaluation of a patient’s anticipated clinical
outcome and may help to inform clinical trials evaluat-
ing therapies to prevent and treat ARDS.
The Large observational study to UNderstand the
Global impact of Severe Acute respiratory FailurE
(LUNG SAFE) undertaken in 459 ICUs in 50 countries
[21] provides a unique opportunity to evaluate associa-
tions between pre-existing diabetes mellitus and the
presence of ARDS in critically ill patients with acute
hypoxemic respiratory failure. Secondary objectives of
this analysis were to explore for any association of dia-
betes mellitus with the progression of AHRF to ARDS,
and subsequent clinical outcome.
Methods
Study design
An ancillary analysis of LUNG SAFE was performed.
This was a global, multi-centre prospective cohort study
that enrolled 4499 patients with AHRF in 459 ICUs
across 50 countries. The details of this study have previ-
ously been described [21]. Briefly, all patients admitted
to a participating ICU were screened daily for AHRF
(defined as the concurrent presence of (1) a ratio of par-
tial pressure of arterial blood oxygen content to inspired
fraction of oxygen (PaO2:FiO2 ratio) ≤ 300 mmHg, (2)
acute pulmonary infiltrates identified on chest x-ray or
computed tomography and (3) mechanical ventilation
with a positive end-expiratory pressure (PEEP) of at least
5 cmH2O) during an enrolment period of 4 consecutive
weeks in winter. Exclusion criteria were age below
16 years or inability to obtain informed consent (when
required by local regulations).
Data were collected until day 28 (days 1, 2, 3, 5, 7, 14, 21
and 28), ICU discharge or death (whichever occurred earl-
ier). Day 1 was defined as the day in which the patient met
criteria for AHRF (baseline). Outcome data were recorded
at hospital discharge or at day 90 (whichever occurred
earliest). Meaurement of partial pressure of arterial carbon
dioxide (PaCO2) was collected daily. Bicarbonate (HCO
−
3 )
data were not collected, instead the data were derived by
the Henderson–Hasselbalch equation:
HCO−3 ¼ 0:03 PaCO2  10pH−6:1:
Using prospectively identified data, ARDS was defined
according to the Berlin ARDS definition [20]: (1) presence
of AHRF criteria, (2) onset within 1 week of insult or new
or worsening respiratory symptoms, (3) bilateral opacities
on chest x-ray or computed tomography and (4) cardiac
failure not being the primary cause of AHRF. Patients
were identified as having diabetes mellitus if it was a docu-
mented co-morbidity. The data collection form used in
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LUNG SAFE did not allow for inclusion of diabetes type,
medications taken, or glycaemic control, and therefore this
information was not available for this ancillary analysis.
Furthermore, data were only collected for patients who
met AHRF criteria. Each site investigator in LUNG SAFE
was responsible for ensuring data integrity. No specific
guidance on the diagnosis of cardiac failure was given to
sites, and the method used to determine whether it was
the sole explanation for AHRF was not recorded.
Outcomes
The primary outcome was presence of ARDS. This was
defined as meeting criteria for ARDS at any time during
the follow-up period from meeting AHRF criteria.
Secondary outcomes included development of ARDS
(defined as occurring after day 2 from meeting AHRF
criteria), duration of invasive mechanical ventilation, and
hospital mortality (defined as outcome at day 90, or hos-
pital discharge, whichever occurred earliest) in patients
with ARDS. Duration of invasive mechanical ventilation
was calculated as the number of days between the date
of intubation and the date of extubation (or death, if the
patient died during invasive mechanical ventilation).
Statistical analysis
Descriptive statistics included calculation of proportions
for categorical variables and mean (± standard deviation)
for continuous variables. The AHRF population was
stratified according to the presence of diabetes mellitus,
and the statistical difference between groups (diabetic
patients, non-diabetic patients) was evaluated by
chi-square test (or Fisher exact test) for discrete vari-
ables and by t test or Wilcoxon rank sum test for con-
tinuous variables. The Shapiro–Wilks test was applied to
assess normality of data distribution.
Patients were excluded from the primary analysis if
cardiac failure was the only cause of AHRF. All clinical
variables and covariates were entered into multivariable
logistic regression model with variable selection based
on a stepwise approach (forward and backward selection
combined with a significance level of 0.05 both for entry
and retention) to identify a set of independent variables
associated with having ARDS at any time during follow
up and after the second day after meeting AHRF criteria
and with hospital mortality. A documented co-morbidity
of diabetes mellitus (“Diabetes diagnosis”) was locked
into the multivariable model as it was the primary ex-
posure of interest. As most patients in LUNG SAFE met
ARDS criteria within 48 h of AHRF onset [21], those pa-
tients who met ARDS criteria after 48 h were studied
separately, and were deemed to have developed ARDS. If
diabetes mellitus was not detected as a statistically sig-
nificant predictor in the final multivariable logistic re-
gression model, for each outcome the entry of this
variable was forced into the model. We also evaluated in
the models the interaction term “diabetes and presence
of a pulmonary ARDS risk factor” in order to assess a
possible different effect of diabetes mellitus on outcomes
in patients with or without a pulmonary ARDS risk fac-
tor. Results of logistic models are shown as odds ratios
(ORs) with 95% confidence intervals (CIs) and p value.
No assumptions were made for missing data.
To account for the differences in baseline characteristics
between patients with AHRF, propensity score was used to
match (1:1 without replacement) diabetic and non-diabetic
patients. Propensity score was estimated using a logistic
regression model that had “presence of diabetes” as the re-
sponse variable and that contained as predictors sex, age,
body mass index (BMI), non-pulmonary Sequential Organ
Failure Assessment (SOFA) score (adjusted for missing
values), co-morbidities (chronic liver failure, chronic renal
failure, chronic heart failure, haematologic neoplasm, im-
munosuppression, active neoplasm, chronic obstructive
pulmonary disease (COPD) or home ventilation), ARDS
risk factors and ventilator variables at baseline. The bal-
ance in measured variables between groups (diabetic and
non-diabetic subjects) has been assessed using standar-
dised difference and a value of less than 0.10 likely denoted
a negligible imbalance. The association between diabetes
mellitus and outcomes of interest was assessed in matched
samples using McNemar’s test for dichotomous outcomes
and Wilcoxon signed ranks test for continuous outcomes.
Kaplan–Meier analysis was applied to estimate the prob-
ability of hospital mortality within 90 days of AHRF onset.
It was assumed that patients discharged alive from hos-
pital before 90 days were alive at day 90. The difference in
survival curves between diabetic and non-diabetic patients
was evaluated using the log-rank test.
All p values were two-sided, and a p value less than 0.05
was considered statistically significant. Statistical analyses
were performed using SAS software, version 9.4 (SAS Insti-
tute, Cary, NC, USA) and with R, version 3.3.3. (R Project
for Statistical Computing, https://www.r-project.org/).
Results
AHRF was identified in 4499 patients: 392 patients (8.7%)
were excluded from the primary analysis because their re-
spiratory failure was fully explained by cardiac failure
(Additional file 1: Figure S1). Of the remaining 4107 pa-
tients with AHRF, 3022 patients (73.6%) fulfilled ARDS
criteria within 2 days of AHRF onset (N = 2813; 93.1%) or
developed ARDS during their ICU admission (N = 209;
6.9%). A total of 913 patients (22.2%) had diabetes mellitus
and of these, 657 (72.0%) met ARDS criteria during their
ICU admission (Additional file 1: Table S1). The baseline
characteristics of patients with AHRF are summarised in
Table 1. Patients with diabetes mellitus were older, had a
higher BMI, received mechanical ventilation with larger
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tidal volumes and higher plateau pressures, had more
co-morbidities but were less likely to have a risk factor for
ARDS. Active neoplasm, haematological neoplasm and
immunosuppression occurred more frequently in
non-diabetic patients.
Presence of ARDS (at any time)
There was no difference in the incidence of ARDS between
patients with and without diabetes mellitus (72% with vs.
74% without diabetes mellitus; p = 0.21) (Additional file 1:
Table S1). In multivariable analysis, there was no
Table 1 Baseline characteristics of patients with AHRF (stratified by presence of diabetes)
Overall
(N = 4107)
Diabetic
(N = 913)
Non-diabetic
(N = 3194)
p value
(Diabetic vs. non-diabetic)
Age (years) 61.7 ± 16.7 66.6 ± 13.1 60.3 ± 17.4 < 0.0001
Male – N (%) 2547 (62.0) 575 (63.0) 1972 (61.7) 0.50
BMI (kg/m2)a 27.5 ± 8.3 30.4 ± 11.7 26.6 ± 6.9 < 0.0001
Non-pulmonary SOFA score (adjusted for missing values)b 6.1 ± 4.1 6.2 ± 4.2 6.1 ± 4.0 0.39
ARDS risk factors – N (%) 0.07
Pulmonary 2295 (55.9) 511 (52.0) 1784 (55.9)
Non-pulmonary 833 (20.3) 174 (19.1) 659 (20.6)
Pulmonary and non-pulmonary 559 (13.6) 115 (12.6) 444 (13.9)
No risk factor 420 (10.2) 113 (12.4) 307 (9.6)
Co-morbidities – N (%)
No co-morbidity other than diabetes mellitus 1958 (47.7) 343 (37.6) 1615 (50.6) < 0.0001
Chronic liver failure 161 (3.9) 33 (3.6) 128 (4.0) 0.37
Chronic renal failure 428 (10.4) 205 (22.5) 227 (7.0) < 0.0001
Chronic cardiac failure (NYHA III-IV) 428 (10.4) 156 (17.1) 272 (8.5) < 0.0001
COPD or home ventilation 989 (24.1) 294 (32.2) 695 (21.8) < 0.0001
Active neoplasm 368 (9.0) 61 (6.7) 307 (9.6) 0.006
Immunosuppression 453 (11.0) 73 (8.0) 380 (11.9) 0.0009
Haematologic neoplasm 170 (4.1) 22 (2.4) 148 (4.6) 0.003
Active neoplasm/immunosuppression/haematologic neoplasm 820 (20.0) 134 (14.7) 686 (21.5) < 0.0001
Baseline ventilator variables
PaO2:FiO2 ratio (mmHg)
c 167.5 ± 67.8 169.2 ± 67.1 167.0 ± 68.0 0.35
Tidal volume (ml/kg PBW)d 7.8 ± 2.2 8.0 ± 2.4 7.7 ± 2.1 0.05
Plateau pressure (cmH2O)
e 22.4 ± 5.9 23.3 ± 5.6 22.1 ± 6.0 0.001
PEEP (cmH2O)
f 7.8 ± 3.1 7.8 ± 3.1 7.8 ± 3.1 0.76
Peak inspiratory pressure (cmH2O)
g 24.8 ± 8.7 25.3 ± 8.8 24.7 ± 8.7 0.05
Respiratory rate (breaths/min)h 21.2 ± 8.1 20.9 ± 6.7 21.3 ± 8.4 0.42
Blood pHi 7.34 ± 0.12 7.33 ± 0.13 7.34 ± 0.12 0.06
PaCO2 (mmHg)
j 45.8 ± 15.6 46.0 ± 15.6 45.7 ± 15.6 0.51
Bicarbonate (mmol/L)k 23.6 ± 6.8 23.4 ± 7.1 23.6 ± 6.7 0.36
Data presented as mean ± standard deviation unless otherwise stated
Abbreviations: AHRF acute hypoxaemic respiratory failure ARDS acute respiratory distress syndrome, BMI body mass index, COPD chronic obstructive pulmonary
disease, NYHA New York heart association functional classification, PaCO2 partial pressure of carbon dioxide in arterial blood, PBW predicted body weight,
PEEP positive end-expiratory pressure, SOFA sequential organ failure assessment
a872 diabetic, 3010 non-diabetic, 3882 patients overall
b908 diabetic, 3168 non-diabetic, 4076 patients overall
c911 diabetic, 3175 non-diabetic, 4086 patients overall
d830 diabetic, 2840 non-diabetic, 3670 patients overall
e244 diabetic, 760 non-diabetic, 1004 patients overall
f910 diabetic, 3163 non-diabetic, 4073 patients overall
g864 diabetic, 2985 non-diabetic, 3849 patients overall
h909 diabetic, 3159 non-diabetic, 4068 patients overall
i896 diabetic, 3146 non-diabetic, 4042 patients overall
j894 diabetic, 3146 non-diabetic, 4040 patients overall
k894 diabetic, 3145 non-diabetic, 4039 patients overall
Boyle et al. Critical Care          (2018) 22:268 Page 4 of 14
association between diabetes mellitus and having ARDS
(OR 0.93 (0.78–1.11); p = 0.39). Haematological neoplasm,
baseline PaO2:FiO2 ratio, respiratory rate, PEEP and peak
inspiratory pressure were significantly associated with hav-
ing ARDS, whilst COPD or home ventilation were associ-
ated with a reduced likelihood of having ARDS (Table 2).
No difference in the relationship between diabetes
and incidence of ARDS was detected between patients
with or without a pulmonary risk factor (p = 0.99,
data not shown).
Development of ARDS (after day 2)
A total of 209 patients developed ARDS after 2 days
from meeting AHRF criteria. The proportion of patients
who developed ARDS after day 2 was similar between
the diabetic and non-diabetic cohort (4.8% vs. 5.2%; p =
0.67) (Additional file 1: Table S1).
Patients with diabetes mellitus who developed ARDS
after day 2 were older and had more frequent
co-existing chronic renal failure, than non-diabetic pa-
tients (Additional file 1: Table S2).
In patients who remained at risk of developing
ARDS after day 2 from meeting AHRF criteria (N =
1294), there was no association identified in multivari-
able analysis between diabetes mellitus and developing
ARDS (OR 0.79 (0.54–1.15); p = 0.22). Baseline peak in-
spiratory pressure, age, pulmonary risk factors and the
combination of pulmonary and non-pulmonary risk fac-
tors were all associated with increased likelihood of de-
veloping ARDS after day 2 from meeting AHRF criteria
(Table 3).
Outcomes in ARDS
A total of 3022 patients had ARDS at any time during the
follow-up period (Additional file 1: Table S1). Patients
with diabetes mellitus who developed ARDS were older,
had a higher BMI, received mechanical ventilation at base-
line with higher tidal volumes and plateau pressure, and
had more co-morbidities than non-diabetic patients.
Documented immunosuppression (unrelated to diabetes
mellitus) was more prevalent in those without diabetes
mellitus (Additional file 1: Table S6). The duration of
invasive mechanical ventilation was similar between the
two groups overall (13.4 ± 17.0 days vs. 12.5 ± 13.4 days;
p = 0.70) and in survivors and non-survivors. Hospital
mortality was similar between the two groups (41.6%
with vs. 38.8% without diabetes mellitus; p = 0.19)
(Additional file 1: Table S7). There was no difference in
survival probability between patients with and without
diabetes mellitus (log-rank test, p = 0.28) (Fig. 1).
There was no association between diabetes mellitus
and hospital mortality in those that had ARDS at any
time when analysed using a univariate (Additional file 1:
Table S8) or multivariate approach (OR 1.15 (0.93–1.42);
p = 0.19) (Table 4). No difference in the relationship
between diabetes mellitus and hospital mortality was
detected between patients with or without a pulmon-
ary ARDS risk factor (p = 0.26, data not shown). In
patients who developed ARDS after day 2, there was
no association between diabetes mellitus and hospital
mortality (OR 1.07 (0.53–2.17); p = 0.84) (Additional
file 1: Table S10).
Assessing the impact of diabetes mellitus using
propensity score matching
In a matched sample of patients with and without dia-
betes mellitus there was no difference in baseline charac-
teristics (Additional file 1: Table S11). In this cohort of
patients, diabetes mellitus was not associated with hav-
ing ARDS (72.0% with vs. 72.8% without diabetes
Table 2 Multivariable analysis of factors associated with
having ARDS
Variable Odds ratio
(95% CI)
p value
Diabetes mellitus diagnosis 0.93 (0.78, 1.11) 0.39
Baseline PaO2:FiO2 ratio (mmHg) 0.996 (0.994, 0.997) < 0.0001
Baseline respiratory rate (breaths/min) 1.03 (1.02, 1.04) < 0.0001
Baseline PEEP (cmH2O) 1.06 (1.04, 1.11) < 0.0001
Baseline peak inspiratory
pressure (cmH2O)
1.02 (1.01, 1.03) 0.0001
ARDS risk factorsa
Pulmonary risk factors 1.93 (1.53, 2.45) < 0.0001
Non-pulmonary risk factors 1.50 (1.15, 1.95) 0.003
Pulmonary and non-pulmonary
risk factors
1.89 (1.40, 2.53) < 0.0001
COPD or home ventilation 0.78 (0.65, 0.93) 0.005
Haematologic neoplasm 1.60 (1.02, 2.52) 0.04
Analysis based on data from 3814 observations
Abbreviations: ARDS acute respiratory distress syndrome, CI confidence interval,
COPD chronic obstructive pulmonary disease, PEEP positive
end-expiratory pressure
aTo estimate the odds ratio, the reference category is “No risk factor”
Table 3 Multivariable analysis for developing ARDS after day 2
Variable Odds-ratio
(95% CI)
p value
Diabetes mellitus diagnosis 0.79 (0.54, 1.15) 0.22
Age (years) 1.01 (1.00, 1.02) 0.03
ARDS risk factorsa
Pulmonary risk factors 2.03 (1.16, 3.54) 0.01
Non-pulmonary risk factors 1.66 (0.90, 3.08) 0.11
Pulmonary and non-pulmonary risk factors 2.32 (1.20, 4.48) 0.01
Baseline peak inspiratory pressure (cmH2O) 1.03 (1.01, 1.05) 0.007
Analysis based on data from 1194 observations
Abbreviations: ARDS acute respiratory distress syndrome, CI confidence interval
aTo estimate odds ratio, the reference category is “No risk factor”
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mellitus; p = 0.77), nor with developing ARDS after day
2 (5.2% vs. 5.7%; p = 0.52), nor with hospital mortality
(40.3% vs. 38.3%; p = 0.48) (Additional file 1: Table S12).
Presence of diabetes mellitus and respiratory muscle
dysfunction
Additional file 1: Figure S2, shows blood PaCO2 (panel
A) and bicarbonate (panel B) over time in diabetic and
non-diabetic patients with AHRF. At day 5 after meeting
AHRF criteria, patients with diabetes mellitus had a
higher blood bicarbonate level, but no difference in
blood PaCO2. In contrast, at day 14, patients with dia-
betes mellitus had a higher PaCO2 but did not have any
difference in blood bicarbonate, compared to patients
without diabetes mellitus.
Discussion
In this large, global, multi-centre prospective observa-
tional study of patients with AHRF, pre-existing diabetes
mellitus was not associated with the presence of ARDS
in patients who have AHRF not fully explained by car-
diac failure. In patients who remained at risk of develop-
ing ARDS after 48 h from having AHRF, there was no
association between diabetes mellitus and developing
ARDS. Finally, in both cohorts, diabetes mellitus did not
modify outcomes.
Previous studies have evaluated whether there is an as-
sociation between diabetes mellitus and risk of ARDS
[9–16, 22], although the results are inconsistent. The
LUNG SAFE cohort includes all patients meeting ARDS
criteria and provide more robust data than prior obser-
vational studies because of the frequency of clinician
Fig. 1 Hospital survival in diabetic and non-diabetic patients with acute respiratory distress syndrome (ARDS). Kaplan–Meier graph shows survival
status for patients with and without diabetes mellitus. There was no difference in survival probability between the two groups (log-rank test, p = 0.28)
Table 4 Multivariable analysis for hospital mortality in patients with ARDS
Variable Odds ratio (95% CI) p value
Diabetes mellitus diagnosis 1.15 (0.93, 1.42) 0.19
Age (years) 1.02 (1.02, 1.03) < 0.0001
Non-respiratory SOFA (adjusted for missing values) 1.12 (1.10, 1.49) < 0.0001
BMI (kg/m2) 0.98 (0.96, 0.99) < 0.0001
Chronic cardiac failure (NYHA III-IV) 1.36 (1.04, 1.79) 0.03
Haematologic neoplasm 4.05 (2.59, 6.36) < 0.0001
Active neoplasm 1.91 (1.43, 2.56) < 0.0001
Immunosuppression 1.56 (1.19, 2.05) 0.001
Respiratory rate (breaths/min) 1.03 (1.02, 1.04) < 0.0001
Baseline PaO2:FiO2 ratio (mmHg) 0.998 (0.997, 0.999) 0.007
Baseline PEEP (cmH2O) 0.95 (0.93, 0.98) 0.003
Baseline peak inspiratory pressure (cmH2O) 1.01 (1.00, 1.02) 0.05
Blood pH 0.18 (0.09, 0.39) < 0.0001
Analysis based on data from 2633 observations
Abbreviations: BMI body mass index, CI confidence interval, SOFA Sequential Organ Failure Assessment, NYHA New York heart association functional classification,
PaO2:FiO2 ratio of partial pressure of arterial blood oxygen content to inspired fraction of oxygen, PEEP positive end-expiratory pressure
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under-recognition of ARDS [21]. Moreover, that LUNG
SAFE comprises 3022 patients with ARDS from 459
ICUs in 50 countries means the findings are more
generalizable. Although there are fewer patients with
diabetes mellitus, this cohort included many more pa-
tients with ARDS than were included in a meta-analysis
of this topic [23]. The findings presented in this study
are relevant to clinicians evaluating the risk of a patient
with a pre-existing history of diabetes mellitus develop-
ing ARDS in the setting of AHRF, as well as their
outcome.
The limitations of this study include those inherent in
observational studies. Epidemiological studies suggest
that 5–15% of patients admitted to the ICU have unrec-
ognised diabetes mellitus [8]. Given that data were not
collected during LUNG SAFE to identify patients with
unrecognised diabetes mellitus, a proportion of patients
will be incorrectly categorised. Furthermore, this was
not a pre-specified analysis in the LUNG SAFE study,
and therefore does not include all the variables that
would be of interest when investigating diabetes mellitus
and ARDS. As a consequence, it is only possible to ad-
just for confounding factors that were collected as part
of LUNG SAFE [21]. Like most of the previously pub-
lished data, this cohort was not separated into different
types of diabetes mellitus. Although patients with dia-
betes mellitus had a significantly higher BMI compared
with non-diabetic patients (Table 1), we are unable to
confirm if this reflects the majority of patients with dia-
betes mellitus being diagnosed as having type 2 diabetes
mellitus. This is potentially important because of the dif-
ferent pathophysiological processes between the various
forms of diabetes mellitus that may exert different effects
in ARDS. However, in an exploratory analysis of a previ-
ous observational study, it was identified that both type 1
and type 2 diabetes mellitus were independently associ-
ated with reduced development of ARDS [14]. The re-
sults presented in this study are hypothesis generating.
Any risk or protective effect associated with diabetes
mellitus may be modified by the magnitude of
pre-existing glucose intolerance, chronic end-organ
complications of diabetes mellitus and chronic
glucose-lowering drugs [24, 25]. Accordingly, future in-
vestigations of the relationship between diabetes melli-
tus and ARDS should aim to have a more rigorous
screening process for diabetes mellitus and should con-
sider evaluating an association between different types
of diabetes mellitus and ARDS, as well as the con-
founding effects of treatment.
In LUNG SAFE, the criteria for AHRF determined that
patients who were included in the analysis had signifi-
cant lung injury at the point of entry into the study.
Whilst this describes a significant proportion of patients
who develop ARDS, the cohort of patients “at risk” of
ARDS include those with less significant physiological
derangement (e.g. patients with pneumonia but a PaO2:-
FiO2 ratio > 300 mmHg), and therefore does not include
all patients at risk of ARDS. The LUNG SAFE study did
not collect detailed data on all screened patients
(Additional file 1: Figure S1). Therefore, it was not
possible to assess the relationship between diabetes mel-
litus and ARDS in all patients at risk. This includes pa-
tients with respiratory failure who were not receiving
ventilatory support, both within and outside the ICU en-
vironment, therefore limiting the applicability of these
findings. Finally, it is possible that the sample of patients
developing ARDS after day 2 was too small to detect an
association with diabetes mellitus.
In this analysis of the LUNG SAFE cohort, patients who
had AHRF only due to cardiac failure were excluded, pro-
viding a clearer description of the relationship between
diabetes mellitus, ARDS and outcomes of AHRF. When
these patients were included in the analysis, diabetes melli-
tus was associated with a reduced risk of developing ARDS
(data not shown). This is explained by more patients with
diabetes mellitus having their AHRF fully explained by car-
diac failure (11.6% with vs. 7.8% without diabetes mellitus;
p = 0.0002). Most prior observational studies that demon-
strated a protective effect of diabetes mellitus on ARDS,
did not exclude patients who developed cardiac failure
from their at-risk population [9, 10, 12, 14]. In one study
that excluded patients with cardiogenic pulmonary
oedema at the onset of septic shock, patients with diabetes
mellitus developed ARDS less frequently than those pa-
tients without diabetes mellitus; however, in a final mul-
tiple logistic regression analysis diabetes mellitus was not
significantly associated with ARDS [16]. This demonstrates
that combining patients who develop cardiac failure with
those that have neither ARDS nor cardiac failure can cause
a bias in the estimates of the effect of diabetes mellitus on
ARDS [16], and the results presented in this analysis of
LUNG SAFE support that finding. Future studies evaluat-
ing exposure risk in ARDS should consider excluding pa-
tients who develop acute hypoxaemic respiratory failure
due to cardiac failure in their risk analysis.
Most patients met ARDS criteria within the first 48 h
of having AHRF. In those patients that developed ARDS
(i.e. after day two from AHRF), there was no association
between diabetes mellitus and ARDS. This expands on
the understanding gathered from previous observational
studies. Patients with diabetes mellitus received more in-
jurious mechanical ventilation at baseline (Table 1), and
it is possible that ventilator-induced lung injury negated
any protective effect that diabetes mellitus has upon the
development of ARDS. There was no statistically signifi-
cant association between diabetes mellitus and reduction
in mortality in those who developed ARDS, a finding
that supports prior observational data [9, 10, 12, 14].
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The results of most previous studies have demonstrated
that diabetes mellitus is not associated with increased ICU
mortality [17–19]. However, in some circumstances dia-
betes mellitus may have a negative effect upon patients’
health and outcome from disease. For example, during the
2009 H1N1 influenza pandemic, diabetes mellitus was asso-
ciated with more severe infection and with a greater risk of
death [26]. Similarly, diabetes mellitus is associated with an
increased risk of hospitalisation from community-acquired
pneumonia and bacterial infection [27], with patients
< 40 years of age at the highest risk when compared
with age-matched controls [28]. ARDS can be
sub-divided into “direct” and “indirect” based on the
underlying insult, and both influenza and
community-acquired pneumonia would be considered
direct insults. Given the association between diabetes
mellitus and more severe disease, it is plausible that
there is a harmful association between diabetes melli-
tus and ARDS in patients who have direct risk factors.
However, previous data have demonstrated that dia-
betes mellitus is independently associated with reduced
risk of mortality in direct ARDS (defined as ARDS as-
sociated with gastric aspiration or pneumonia) [29].
Interestingly, in this ancillary analysis of LUNG SAFE,
there was no association between diabetes mellitus and
ARDS or hospital mortality among patients who had at
least one pulmonary risk factor. This difference may be ex-
plained by the difference between the included patients, as
LUNG SAFE included inhalational injury, pulmonary con-
tusion, pulmonary vasculitis and drowning, alongside gas-
tric aspiration and pneumonia, as direct risk factors.
Diabetes mellitus may act as a confounding factor for re-
ceiving insulin therapy, and it may be that the previously
observed protective effects of diabetes mellitus in ARDS
may reflect an immune-modulatory effect of medications
such as insulin [30]. Pre-clinical studies have demonstrated
protective benefits of insulin therapy in lung injury second-
ary to trauma [31], and when used to maintain euglycaemia
in ARDS secondary to endotoxaemia [32]. However, other
data suggest that immune hypo-responsiveness in diabetes
mellitus is reversed by insulin therapy, and associated with
alveolar neutrophil infiltration and increased alveolar con-
centration of pro-inflammatory cytokines in lipopolysac-
charide (LPS)-induced lung injury [33], suggesting that
insulin may restore immune function and therefore could
reverse some of the protective effects of diabetes mellitus
in relation to ARDS. Other medications that have been
identified as having potential immuno-modulatory effects,
including metformin [34, 35], aspirin [36] ace-inhibitors [4]
and statins [37] may act as confounding factors in this
study. Diabetic polyneuropathy has been demonstrated to
affect respiratory neuromuscular function in patients with
type 2 diabetes mellitus [38], but it is unknown whether
diabetic polyneuropathy has a significant impact in patients
with AHRF. In an assessment of blood PaCO2 and bi-
carbonate over time in patients with and without dia-
betes mellitus, there was no trend identified to suggest
that respiratory muscle insufficiency was greater in
either cohort. However, this analysis is limited, and
further assessment of this important, potential con-
founding factor, may be warranted.
Patients with diabetes mellitus had significant differ-
ences in their baseline co-morbidities when compared to
patients without diabetes mellitus. To account for this, a
post-hoc propensity score was used to match patients
with and without diabetes mellitus. This analysis did not
demonstrate an association between diabetes mellitus
and outcomes of interest, suggesting that the absence of
an effect of diabetes mellitus in the wider AHRF popula-
tion is unlikely to have been due to baseline population
imbalance.
Conclusions
In this global, multi-centre, prospective observational
study of mechanically ventilated patients with AHRF,
there was no association identified between diabetes
mellitus and ARDS or outcomes. These findings are hy-
pothesis generating and may inform clinicians about the
risk of developing ARDS and the outcomes of patients
with diabetes mellitus and AHRF. Further research is re-
quired to establish if there is an effect between the type
and severity of diabetes mellitus, as well as the con-
founding effect of treatment for this condition, and the
development and outcome of ARDS.
Additional file
Additional file 1: Supplementary analysis, figures and tables. Contains
supplementary results and data from this analysis of the LUNG SAFE
database. Included are results relating to outcomes from patients who
developed ARDS after day 2, a flowchart describing the study population,
and tables supplementary to the results presented in the main
manuscript. (DOCX 832 kb)
Abbreviations
AHRF: Acute hypoxemic respiratory failure; ARDS: Acute respiratory distress
syndrome; BMI: Body mass index; CI: Confidence interval; COPD: Chronic
obstructive pulmonary disease; ICU: Intensive care unit; LUNG SAFE: Large
observational study to understand the global impact of severe acute
respiratory failure; NYHA: New York Heart Association; OR: Odds ratio;
PaCO2: Partial pressure of arterial carbon dioxide; PaO2:FiO2 ratio: Ratio of
partial pressure of arterial blood oxygen content to inspired fraction of
oxygen; PEEP: Positive end-expiratory pressure; SOFA: Sequential Organ
Failure Assessment
Acknowledgements
The authors thank all study sites, investigators, coordinators and national
associations who contributed to LUNG SAFE.
National coordinators for LUNG SAFE
Argentina: Fernando Rios; Australia/New Zealand: Frank Van Haren;
Bangladesh: Mohammad Omar Faruq; Belgium: Sottiaux T, Depuydt P; Bolivia:
Fredy S Lora; Brazil: Luciano Cesar Azevedo; Canada: Eddy Fan; Chile:
Guillermo Bugedo; China: Haibo Qiu; Colombia: Marcos Gonzalez; Costa Rica:
Juan Silesky; Czech Republic: Vladimir Cerny; Denmark: Jonas Nielsen;
Boyle et al. Critical Care          (2018) 22:268 Page 8 of 14
Ecuador: Manuel Jibaja; France: Tài Pham; Germany: Hermann Wrigge;
Greece: Dimitrios Matamis; Guatemala: Jorge Luis Ranero; Hong Kong:
Charles Gomersall; India: Pravin Amin; Iran: S.M. Hashemian; Ireland: Kevin
Clarkson; Italy: Giacomo Bellani; Japan: Kiyoyasu Kurahashi; Korea: Younsuck
Koh; Mexico: Asisclo Villagomez; Morocco: Amine Ali Zeggwagh; Netherlands:
Leo M Heunks; Norway: Jon Henrik Laake; Pakistan: Waqar Kashif; Panama:
Jorge Synclair; Philippines: Jose Emmanuel Palo; Portugal: Antero do Vale
Fernandes; Romania: Dorel Sandesc; Saudi Arabia: Yaasen Arabi; Serbia: Vesna
Bumbasierevic; Spain: Nicolas Nin, Jose A Lorente; Sweden: Anders Larsson;
Switzerland: Lise Piquilloud; Thailand: Boonsong Patjanasoontorn; Tunisia:
Fekri Abroug; United Kingdom: Daniel F McAuley, Lia McNamee; Uruguay:
Javier Hurtado; USA: Ed Bajwa; Venezuela: Gabriel Démpaire.
National Societies/Networks Endorsing LUNG SAFE
ANZICS Clinical Trials Group, Réseau Européen de Recherche en Ventilation
Artificielle (ReVA Network); Irish Critical Care Trials Group; Société de
Réanimation de Langue Française (SRLF); Société Française d’Anesthésie et de
Réanimation (SFAR); Società Italiana Anestesia, Analgesia, Rianimazione e
Terapia Intensiva (SIAARTI); The Japanese Society of Intensive Care Medicine
(JSICM); Nonprofit Organisation Japanese Society of Education for Physicians
and Trainees in Intensive Care (JSEPTIC); UK Intensive Care Society.
Study coordination
Guy M Francois (European Society of Intensive Care Medicine, Brussels,
Belgium).
Data revision and management
Francesca Rabboni (University Of Milan-Bicocca, Monza, Italy), Fabiana
Madotto (University Of Milan-Bicocca, Monza, Italy), Sara Conti (University Of
Milan-Bicocca, Monza, Italy).
Site investigators by country
Albania: Uhc Mother Theresa (Tirana): Hektor Sula, Lordian Nunci; University
Hospital Shefqet Ndroqi (Tirana): Alma Cani.
Argentina: Clinica De Especialidades (Villa Maria): Alan Zazu; Hospital Dr Julio
C Perrando (Resistencia): Christian Dellera, Carolina S Insaurralde; Sanatorio
Las Lomas (San Isidro, Buenos Aires): Risso V Alejandro; Sanatorio De La
Trinidad San Isidro (San Isidro): Julio Daldin, Mauricio Vinzio; Hospital Español
De Mendoza (Godoy Cruz - Mendoza): Ruben O Fernandez; Hospital Del
Centenario (Rosario): Luis P Cardonnet, Lisandro R Bettini; San Antonio
(Gualeguay (Entre Rios)): Mariano Carboni Bisso, Emilio M Osman; Cemic
(Buenos Aires): Mariano G Setten, Pablo Lovazzano; Hospital Universitrario
Austral (Pilar): Javier Alvarez, Veronica Villar; Hospital Por + Salud (Pami) Dr
Cesar Milstein (Buenos Aires): Norberto C Pozo, Nicolas Grubissich; Sanatorio
Anchorena (Buenos Aires): Gustavo A Plotnikow, Daniela N Vasquez;
Sanatorio De La Trinidad Mitre (Buenos Aires): Santiago Ilutovich, Norberto
Tiribelli; Hospital Luis Lagomaggiore (Mendoza): Ariel Chena, Carlos A
Pellegrini; H.I.G.A San Martín (La Plata): María G Saenz, Elisa Estenssoro;
Hospital Misericordia (Cordoba): Matias Brizuela, Hernan Gianinetto; Sanatorio
Juncal (Temperley): Pablo E Gomez, Valeria I Cerrato; Hospital D. F. Santojanni
(Buenos Aires): Marco G Bezzi, Silvina A Borello; Hospital Alejandro Posadas
(Buenos Aires): Flavia A Loiacono, Adriana M Fernande.
Australia: St. Vincents Hospital, Sydney (Darlinghurst): Serena Knowles, Claire
Reynolds; St George Public Hospital (Kogarah): Deborah M Inskip, Jennene J
Miller; Westmead Hospital (Westmead): Jing Kong, Christina Whitehead;
Flinders Medical Centre (Bedford Park, South Australia): Shailesh Bihari; John
Hunter Hospital (Newcastle): Aylin Seven, Amanda Krstevski; Canberra
Hospital (Garran): Helen J Rodgers, Rebecca T Millar; Calvary Mater Newcastle
(Waratah): Toni E Mckenna, Irene M Bailey; Cabrini Hospital (Melbourne):
Gabrielle C Hanlon; Liverpool Hospital (Liverpool): Anders Aneman, Joan M
Lynch; Coffs Harbour Health Campus (Coffs Harbour): Raman Azad, John
Neal; Sir Charles Gairdner Hospital (Nedlands): Paul W Woods, Brigit L
Roberts; Concord Hospital (Concord): Mark R Kol, Helen S Wong.
Austria: General Hospital Of Vienna/Medical University Of Vienna (Vienna):
Katharina C Riss, Thomas Staudinger;
Belgium: Cliniques universitaires St Luc, UCL (Brussels): Xavier Wittebole,
Caroline Berghe; CHU Dinant-Godinne (Yvoir): Pierre A Bulpa, Alain M Dive;
AZ Sint Augustinus Veurne (Veurne): Rik Verstraete, Herve Lebbinck; Ghent
University Hospital (Ghent): Pieter Depuydt, Joris Vermassen;; University
Hospitals Leuven (Leuven): Philippe, Meersseman, Helga Ceunen.
Brazil: Hospital Renascentista (Pouso Alegre): Jonas I Rosa, Daniel O Beraldo;
Vitoria Apart Hospital (Serra): Claudio Piras, Adenilton M Rampinelli; Hospital
Das Clinicas (São Paulo): Antonio P Nassar Jr.; Hospital Geral Do Grajaù (São
Paulo): Sergio Mataloun, Marcelo Moock; Evangelical Hospital (Cachoeiro De
Itapemirim/Espírito Santo): Marlus M Thompson, Claudio H Gonçalves-,;
Hospital Moinhos De Vento (Porto Alegre): Ana Carolina P Ant ônio, Aline
Ascoli; Hospital Alvorada Taguatinga (Taguatinga): Rodrigo S Biondi, Danielle
C Fontenele; Complexo Hospitalar Mngabeira Tarcisio Burity (Joao Pessoa):
Danielle Nobrega, Vanessa M Sales.
Brunei Darussalam: Raja Isteri Pengiran Anak Saleha (Ripas) Hospital (Bandar
Seri Begawan): Dr Suresh Shindhe, Dr Dk Maizatul Aiman B Pg Hj Ismail.
Canada: Medical-Surgical ICU of St Michael’s Hospital (Toronto): John Laffey,
Francois Beloncle; St. Josephs Health Centre (Toronto): Kyle G Davies, Rob
Cirone; Sunnybrook Health Sciences Center (Toronto): Venika Manoharan,
Mehvish Ismail; Toronto Western Hospital (Toronto): Ewan C Goligher,
Mandeep Jassal; Medical Surgical ICU of the Toronto General Hospital
(Toronto): Niall D. Ferguson, Erin Nishikawa, Areej Javeed; Cardiovascular ICU
of St Michael’s Hospital (Toronto): Gerard Curley, Nuttapol Rittayamai;
Cardiovascular ICU of the Toronto General Hospital (Toronto): Matteo Parotto,
Mount Sinai Hospital (Toronto): Sangeeta Mehta, Jenny Knoll; Trauma-Neuro
ICU of St Michael’s Hospital (Toronto): Antoine Pronovost, Sergio Canestrini.
Chile: Hospital Clínico Pontificia Universidad Católica De Chile (Santiago):
Alejandro R Bruhn, Patricio H Garcia; Hospital Militar De Santiago (Santiago):
Felipe A Aliaga, Pamela A Farías; Clinica Davila (Santiago): Jacob S Yumha;
Hospital Guillermo Grant Benavente (Concepcion): Claudia A Ortiz, Javier E
Salas; Clinica Las Lilas (Santiago): Alejandro A Saez, Luis D Vega; Hospital
Naval Almirante Nef (Viña Del Mar): Eduardo F Labarca, Felipe T Martinez;
Hospital Luis Tisné Brousse (Penanolen): Nicolás G Carreño, Pilar Lora.
China: The Second Affiliated Hospital Of Harbin Medical University (Harbin):
Haitao Liu; Nanjing Zhong-Da Hospital, Southeast University (Nanjing): Haibo
Qiu, Ling Liu; The First Affiliated Hospital Of Anhui Medical University (Hefei):
Rui/Tang, Xiaoming Luo; Peking University People’s Hospital (Beijing):
Youzhong An, Huiying Zhao; Fourth Affiliated Hospital Of Harbin Medical
University (Harbin): Yan - Gao, Zhe - Zhai; Nanjing Jiangbei Peoples Hospital
Affiliated To Medical School Of Southeast University (Nanjing): Zheng L Ye,
Wei Wang; The First Affiliated Hospital Of Dalian Medical Unvercity (Dalian):
Wenwen Li, Qingdong Li; Subei Peoples Hospital Of Jiangsu Province
(Yanghzou): Ruiqiang Zheng; Jinling Hospital (Nanjing): Wenkui Yu, Juanhong
Shen; Urumqi General Hospital (Urumqi): Xinyu Li; Intensive Care Unit, First
Affiliated Hospital Of Wanna Medical College, Yijishan Hospital, (Wuhu): Tao
Yu, Weihua Lu; Sichuan Provincial Peoples Hospital (Chengdu): Ya Q Wu, Xiao
B Huang; Hainan Province Peoples Hospital (Haikou): Zhenyang He; Peoples
Hospital Of Jiangxi Province (Nanchang): Yuanhua Lu; Qilu Hospital Of
Shandong University (Jinan): Hui Han, Fan Zhang; Zhejiang Provincial
Peoples Hospital (Hangzhou): Renhua Sun; The First Affiliated Hospital Of
Bengbu Medical College (Bengbu, Anhui): Hua X Wang, Shu H Qin; Nanjing
Municipal Government Hospital (Nanjing): Bao H Zhu, Jun Zhao; The First
Hospital Of Lanzhou University (Lanzhou): Jian / Liu, Bin/Li; The First Affiliated
Hospital Of Chongqing University Of Medical Science (Chongqing): Jing L
Liu, Fa C Zhou; Xuzhou Central Hospital, Jiangsu Province, China (Xuzhou):
Qiong J Li, Xing Y Zhang; The First Peoples Hospital Of Foshan (Foshan):
Zhou Li-Xin, Qiang Xin-Hua; The First Affiliated Hospital Of Guangxi Medical
University (Nanning): Liangyan Jiang; Renji Hospital, Shanghai Jiao Tong
University School Of Medicine (Shanghai): Yuan N Gao, Xian Y Zhao; First
Hospital Of Shanxi Medical University (Taiyuan): Yuan Y Li, Xiao L Li;
Shandong Provincial Hospital (Jinan): Chunting Wang, Qingchun Yao; Fujian
Provincial Hospital (Fuzhou): Rongguo Yu, Kai Chen; Henan Provincial
People’s Hospital (Zhengzhou): Huanzhang Shao, Bingyu Qin; The Second
Affiliated Hospital Of Kunming Medical University (Kunming City): Qing Q
Huang, Wei H Zhu; Xiangya Hospital, Central South University (Changsha): Ai
Y Hang, Ma X Hua; The First Affiliated Hospital Of Guangzhou Medical
University (Guangzhou): Yimin Li, Yonghao Xu; Peoples Hospital of Hebei
Province (Shijiazhuang): Yu D Di, Long L Ling; Guangdong General Hospital
(Guangzhou): Tie H Qin, Shou H Wang; Beijing Tongren Hospital (Beijing):
Junping Qin; Jiangsu Province Hospital (Nanjing): Yi Han, Suming Zhou.
Colombia: Fundación Valle Del Lili (Cali): Monica P Vargas.
Costa Rica: Hospital San Juan De Dios: Juan I Silesky Jimenez, Manuel A
González Rojas; Hospital San Juan De Dios (San José): Jaime E Solis-Quesada,
Christian M Ramirez-Alfaro.
Czech Republic: University Hospital Of Ostrava (Ostrava): Jan Máca, Peter
Sklienka;
DENMARK: Aarhus Universitetshospital (Aarhus N): Jakob Gjedsted, Aage
Christiansen; Rigshopitalet: Jonas Nielsen.
Ecuador: Hospital Militar (Quito): Boris G Villamagua, Miguel Llano.
France: Clinique du Millénaire (Montpellier): Philippe Burtin, Gautier
Buzancais; Centre Hospitalier (Roanne): Pascal Beuret, Nicolas Pelletier; CHU
Boyle et al. Critical Care          (2018) 22:268 Page 9 of 14
d’Angers (Angers): Satar Mortaza, Alain Mercat; Hôpital Marc Jacquet (Melun):
Jonathan Chelly, Sébastien Jochmans; CHU de Caen (Caen): Nicolas Terzi, Cédric
Daubin; Henri Mondor Hospital (Créteil): Guillaume Carteaux, Nicolas de Prost;
Cochin Hospital (Paris): Jean-Daniel Chiche, Fabrice Daviaud; CHU Tenon (Paris):
Tài Pham, Muriel Fartoukh; CH Mulhouse-Emile Muller (Mulhouse): Guillaume
Barberet, Jerome Biehler; Archet 1 University Hospital (Nice): Jean Dellamonica,
Denis Doyen; Hopital Sainte Musse (Toulon): Jean-Michel Arnal, Anais Briquet;
Hopital Nord - Réanimation des Détresses Respiratoires et Infections Sévères
(Marseille): Fanny Klasen, Laurent Papazian; HEGP (Paris): Arnaud Follin; Louis
Mourier Hospital (Colombes): Damien Roux, Jonathan Messika; Centre
Hospitalier de Dax (Dax): Evangelos Kalaitzis; Réanimation Médicale, GH Pitié-
Salpêtrière (Paris): Laurence Dangers, Alain Combes; Ap-Hp Ambroise Paré
(Boulogne-Billancourt): Siu-Ming Au; University Hospital Rouen (Rouen): Gaetan
Béduneau, Dorothée Carpentier; CHU Amiens (Amiens - Salouel): Elie H
Zogheib, Herve Dupont; Centre Hospitalier Intercommunal Robert Ballanger
(Aulnay Sous Bois): Sylvie Ricome, Francesco L Santoli; Centre Hospitalier René
Dubos (Pontoise): Sebastien L Besset; CHI Portes de l’Oise (Beaumont Sur Oise):
Philippe Michel, Bruno Gelée; Archet 2 University Hospital (Nice): Pierre-Eric
Danin, Bernard Goubaux; Centre Hospitalier Pierre Oudot (Bourgoin Jallieu):
Philippe J Crova, Nga T Phan; CH Dunkerque (Dunkerque): Frantz Berkelmans;
Centre Hospitalier de Belfort Montbéliard (Belfort): Julio C Badie, Romain
Tapponnier; Centre Hospitalier Emile Muller (Mulhouse): Josette Gally, Samy
Khebbeb; Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg
(Strasbourg): Jean-Etienne Herbrecht, Francis Schneider; Centre Hospitalier de
Dieppe (Dieppe): Pierre-Louis M Declercq, Jean-Philippe Rigaud; Bicêtre (Le
Kremin-Bicetre): Jacques Duranteau, Anatole Harrois; CHU Gabriel Montpied
(Clermont-Ferrand): Russell Chabanne, Julien Marin; CHU Estaing (Clermont-
Ferrand): Jean-Michel Constantin, Sandrine Thibault; CHI Eure-Seine Evreux
(Evreux): Mohammed Ghazi, Messabi Boukhazna; Centre Hospitalier de Châlons
en Champagne (Châlons en Champagne): Salem Ould Zein; CH Beauvais
(Beauvais): Jack R Richecoeur, Daniele M Combaux; Centre Hospitalier Le Mans
(Le Mans): Fabien Grelon, Charlene Le Moal; Hôpital Fleyriat (Bourg en Bresse):
Elise P Sauvadet, Adrien Robine; Hôpital Saint Louis (Paris): Virginie Lemiale,
Danielle Reuter; Pneumologie et Réanimation Médicale, Hôpital Pitié-
Salpêtrière (Paris): Martin Dres, Alexandre Demoule; Centre Hospitalier
Gonesse (Gonesse): Dany Goldgran-Toledano; Hôpital Croix Rousse (Lyon):
Loredana Baboi, Claude Guérin.
Germany: St. Nikolaus-Stiftshospital (Andernach): Ralph Lohner;
Fachkrankenhaus Coswig Gmbh (Coswig):Jens Kraßler, Susanne Schäfer;
University Hospital Frankfurt (Frankfurt am Main): Kai D Zacharowski, Patrick
Meybohm; Department of Anaesthesia & Intensive Care Medicine, University
Hospital of Leipzig (Leipzig): Andreas W Reske, Philipp Simon; Asklepios Klinik
Langen (Langen): Hans-Bernd F Hopf, Michael Schuetz; Städtisches
Krankenhaus Heinsberg (Heinsberg): Thomas Baltus.
Greece: Hippokrateion General Hospital Of Athens (Athens): Metaxia N
Papanikolaou, Theonymfi G Papavasilopoulou; Gh Ahepa (Thessaloniki):
Giannis A Zacharas, Vasilis Ourailogloy; Hippokration General Hospital of
Thessaloniki (Thessaloniki): Eleni K Mouloudi, Eleni V Massa; Hospital General
of Kavala (Kavala): Eva O Nagy, Electra E Stamou; Papageorgiou General
Hospital (Thessaloniki): Ellada V Kiourtzieva, Marina A Oikonomou.
Guatemala: Hospital General De Enfermedades, Instituto Guatemalteco De
Seguridad Social (Ciudad De Guatemala): Luis E Avila; Centro Médico Militar
(Guatemala): Cesar A Cortez, Johanna E Citalán.
India: Deenanath Mangeshkar Hospital And Research Center (Pune): Sameer
A Jog, Safal D Sable; Care Institute Of Medical Sciences (CIMS) Hospital
(Ahmedabad): Bhagyesh Shah; Sanjay Gandhi Postgraduate Institute Of
Medical Sciences (SGPGIMS) (Lucknow): Mohan Gurjar, Arvind K Baronia;
Rajasthan Hospital (Ahmedabad): Mohammedfaruk Memon; National Institute
Of Mental Health And Neuro Sciences (NIMHANS) (Bangalore): Radhakrishnan
Muthuchellappan, Venkatapura J Ramesh; Anaesthesiology Unit of the
Kasturba Medical College & Dept of Respiratory Therapy, SHOAS, Manipal
University (Manipal): Anitha Shenoy, Ramesh Unnikrishnan; Sanjeevan
Hospital (Pune): Subhal B Dixit, Rachana V Rhayakar; Apollo Hospitals
(Chennai): Nagarajan Ramakrishnan, Vallish K Bhardwaj; Medicine Unit of the
Kasturba Medical College & Dept of Respiratory Therapy, SHOAS, Manipal
University (Manipal): Heera L Mahto, Sudha V Sagar; G Kuppuswamy Naidu
Memorial Hospital (Coimbatore): Vijayanand Palaniswamy, Deeban Ganesan;
IRAN: NRITLD/Masih Daneshvari (Tehran): Seyed Mohammadreza Hashemian,
Hamidreza Jamaati; Milad Hospital (Tehran): Farshad Heidari.
Ireland: St Vincent’s University Hospital (Dublin): Edel A Meaney, Alistair
Nichol; Mercy University Hospital (Cork): Karl M Knapman, Donall O’Croinin;
Cork University Hospital (Cork): Eimhin S Dunne, Dorothy M Breen; Galway
University Hospital (Galway): Kevin P Clarkson, Rola F Jaafar; Beaumont
Hospital (Dublin): Rory Dwyer, Fahd Amir; Mater Misericordiae University
Hospital (Dublin): Olaitan O Ajetunmobi, Aogan C O’Muircheartaigh; Tallaght
Hospital (Dublin): Colin S Black, Nuala Treanor; Saint James’s Hospital
(Dublin): Daniel V Collins, Wahid Altaf.
Italy: Santa Maria delle Croci Hospital (Ravenna): Gianluca Zani, Maurizio
Fusari; Arcispedale Sant’Anna Ferrara. (Ferrara): Savino Spadaro, Carlo A Volta;
Ospedale Profili (Fabriano) (An): Romano Graziani, Barbara Brunettini;
Umberto I Nocera Inferiore (Nocera Inferiore Salerno): Salvatore Palmese;
Azienda Ospedaliera San Paolo - Polo Universitario - Università degli Studi di
Milano (Milan): Paolo Formenti, Michele Umbrello; Sant’Anna (San Fermo
Della Battaglia (Co)): Andrea Lombardo; Spedali Civili Brescia (Brescia):
Elisabetta Pecci, Marco Botteri; Fondazione Irccs Ca Granda, Ospedale
Maggiore Policlinico (Milan): Monica Savioli, Alessandro Protti; University
Campus Bio-Medico of Rome (Rome): Alessia Mattei, Lorenzo Schiavoni;
Azienda Ospedaliera “Mellino Mellini” (Chiari (Bs)): Andrea Tinnirello, Manuel
Todeschini; Policlinico P. Giaccone, University of Palermo (Palermo): Antonino
Giarratano, Andrea Cortegiani; Niguarda Cà Granda Hospital (Milan): Sara
Sher, Anna Rossi; A. Gemelli University Hospital (Rome): Massimo M Antonelli,
Luca M Montini; Ospedale “Sandro Pertini” (Rome): Paolo Casalena, Sergio
Scafetti; ISMeTT IRCCS UPMC (Palermo): Giovanna Panarello, Giovanna
Occhipinti; Ospedale San Gerardo (Monza): Nicolò Patroniti, Matteo Pozzi;
Santa Maria Della Scaletta (Imola): Roberto R Biscione, Michela M Poli;
Humanitas Research Hospital (Rozzano): Ferdinando Raimondi, Daniela
Albiero; Ospedale Desio - Ao Desio-Vimercate (Desio): Giulia Crapelli, Eduardo
Beck; Pinetagrande Private Hospital (Castelvolturno): Vincenzo Pota, Vincenzo
Schiavone; Irccs San Martino Ist (Genova): Alexandre Molin, Fabio Tarantino;
Ospedale San Raffaele (Milano): Giacomo Monti, Elena Frati; Ospedali Riuniti Di
Foggia (Foggia): Lucia Mirabella, Gilda Cinnella; Azienda Ospedaliera Luigi Sacco
- Polo Universitario (Milano): Tommaso Fossali, Riccardo Colombo; A.O.U. Città
della Salute e della Scienza di Torino (Turin): Pierpaolo Terragni Ilaria Pattarino;
Università degli Studi di Pavia-Fondazione IRCCS Policlinico San Matteo (Pavia):
Francesco Mojoli, Antonio Braschi; Ao Ospedale Civile Legnano (Legnano): Erika
E Borotto; Arnas Ospedale Civico Di Cristina Benfratelli (Palermo): Andrea N
Cracchiolo, Daniela M Palma; Azienda Ospedaliera Della Provincia Di Lecco -
Ospedale “A. Manzoni” (Lecco): Francesco Raponi, Giuseppe Foti; A.O. Provincia
Di Lecco - Ospedale Alessandro Manzoni (Lecco): Ettore R Vascotto, Andrea
Coppadoro; Cliniche Universitarie Sassari (Sassari): Luca Brazzi, Leda Floris; IRCCS
Policlinico San Matteo (Pavia): Giorgio A Iotti, Aaron Venti.
Japan: Yokohama City University Hospital (Yokohama): Osamu Yamaguchi,
Shunsuke Takagi; Toyooka Hospital (Toyooka City, Hyogo Prefecture): Hiroki N
Maeyama; Chiba University Hospital (Chiba City): Eizo Watanabe, Yoshihiro
Yamaji; Okayma University Hospital (Okayama): Kazuyoshi Shimizu, Kyoko
Shiozaki; Japanese Foundation for Cancer Research, Cancer Institute Hospital,
Department Of Emergency Medicine And Critical Care (Tokyo): Satoru
Futami; Ibaraki Prefectural Central Hospital (Kasama): Sekine Ryosuke; Tohoku
University Hospital (Sendai-Shi): Koji Saito, Yoshinobu Kameyama; Tokyo
Medical University Hachioji Medical Center (Hachioji, Tokyo): Keiko Ueno;
Tokushima University Hospital (Tokushima): Masayo. Izawa, Nao Okuda;
Maebashi Red Cross Hospital (Gunma Maebashi): Hiroyuki Suzuki, Tomofumi
Harasawa; Urasoe General Hospital (Urasoe): Michitaka Nasu, Tadaaki Takada;
Ohta General Hospital Foundation Ohta Nishinouchi Hospital (Fukushima):
Fumihito Ito; Jichi Medical University Hospital (Shimotsuke): Shin - Nunomiya,
Kansuke - Koyama; Mito Kyodo General Hospital, Tsukuba University Hospital
Mito Medical Center (Mito): Toshikazu Abe; Sendai City Hospital (Sendai):
Kohkichi Andoh, Kohei Kusumoto; Ja Hiroshima General Hospital (Hatsukaichi
City, Hiroshima): Akira Hirata, Akihiro Takaba; Yokohama Rosai Hospital
(Yokohama): Hiroyasu Kimura; Nagasaki University Hospital (Nagasaki): Shuhei
Matsumoto, Ushio Higashijima; Niigata University Medical & Dental Hospital
(Niigata): Hiroyuki Honda, Nobumasa Aoki; Mie University Hospital (Tsu, Mie):
Hiroshi Imai; Yamaguchi University Hospital (Ube, Yamaguchi): Yasuaki Ogino,
Ichiko Mizuguchi; Saiseikai Kumamoto Hospital (Kumamoto City): Kazuya
Ichikado; Shinshu University School Of Medecine (Matsumoto City): Kenichi
Nitta, Katsunori Mochizuki; Kuki General Hospital (Kuki): Tomoaki Hashida;
Kyoto Medical Center (Kyoto): Hiroyuki Tanaka; Fujita Health University
(Toyoake): Tomoyuki Nakamura, Daisuke Niimi; Rakwakai Marutamachi
Hospital (Kyoto): Takeshi Ueda; Osaka University Hospital (Suita City, Osaka
Prefecture): Yozo Kashiwa, Akinori Uchiyama.
Latvia: Paul Stradins Clinical University Hospital (Riga): Olegs Sabelnikovs,
Peteris Oss.
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Lebanon: Kortbawi Hospital (Jounieh): Youssef Haddad.
Malaysia: Hospital Kapit (Kapit): Kong Y Liew.
Mexico: Instituto Nacional De Cancerología, México (Mexico City): Silvio A
Ñamendys-Silva, Yves D Jarquin-Badiola; Hospital De Especialidades “Antonio
Fraga Mouret” Centro Medico Nacional La Raza IMSS (Mexico City): Luis A
Sanchez-Hurtado, Saira S Gomez-Flores; Hospital Regional 1° De Octubre
(Mexico City): Maria C Marin, Asisclo J Villagomez; Hospital General Dr
Manuel Gea Gonzalez (Mexico City): Jordana S Lemus, Jonathan M Fierro;
Hospital General De Zona No. 1 Instituto Mexicano Del Seguro Social Tepic
Nayarit (Tepic): Mavy Ramirez Cervantes, Francisco Javier Flores Mejia; Centro
Medico Dalinde (Mexico D.F.): Dulce Dector, Dulce M Dector; Opd Hospital
Civil De Guadalajara Hospital Juan I Menchaca (Guadalajara): Daniel R
Gonzalez, Claudia R Estrella; Hospital Regional De Ciudad Madero Pemex
(Ciudad Madero): Jorge R Sanchez-Medina, Alvaro Ramirez-Gutierrez; Centro
Médico ABC (Mexico D.F.): Fernando G George, Janet S Aguirre; Hospital
Juarez De Mexico (Mexico City): Juan A Buensuseso, Manuel Poblano.
Morocco: Mohammed V University, University Teaching Ibn Sina Hospital
(Rabat): Tarek Dendane, Amine Ali Zeggwagh; Hopital Militaire D’Instruction
Mohammed V (Rabat): Hicham Balkhi; Errazi (Marrakech): Mina Elkhayari,
Nacer Samkaoui; University Teaching Hospital Ibn Rushd (Casablanca):
Hanane Ezzouine, Abdellatif Benslama; Hôpital des Spécialités de Rabat (HSR)
(Rabat): Mourad Amor, Wajdi Maazouzi.
Netherlands: Tjongerschans (Heerenveen): Nedim Cimic, Oliver Beck; Cwz
(Nijmegen): Monique M Bruns, Jeroen A Schouten; Rijnstate Hospital
(Arnhem): Myra - Rinia, Monique Raaijmakers; Radboud Umc (Nijmegen): Leo
M Heunks, Hellen M Van Wezel; Maastricht University Medical Centre
(Maastricht): Serge J Heines, Ulrich Strauch; Catharinaziekenhuis (Eindhoven):
Marc P Buise; Academic Medical Center (Amsterdam): Fabienne D Simonis,
Marcus J Schultz.
New Zealand: Tauranga Hospital (Tauranga): Jennifer C Goodson, Troy S
Browne; Wellington Hospital (Wellington): Leanlove Navarra, Anna Hunt;
Dunedin Hospital (Dunedin): Robyn A Hutchison, Mathew B Bailey; Auckland
City Hospital (Auckland): Lynette Newby, Colin Mcarthur; Whangarei Base
Hospital (Whangarei): Michael Kalkoff, Alex Mcleod; North Shore Hospital
(Auckland): Jonathan Casement, Danielle J Hacking.
Norway: Ålesund Hospital (Ålesund): Finn H Andersen, Merete S Dolva; Oslo
University Hospital - Rikshospitalet Medical Centre (Oslo): Jon H Laake,
Andreas Barratt-Due; Stavanger University Hospital (Stavanger): Kim Andre L
Noremark, Eldar Søreide; Haukeland University Hospital (Bergen): Brit Å Sjøbø,
Anne B Guttormsen.
Peru: Hospital Nacional Edgardo Rebagliati Martins (Lima): Hector H Leon
Yoshido; Clínica Ricardo Palma (Lima): Ronald Zumaran Aguilar, Fredy A
Montes Oscanoa.
Philippines: The Medical City (Pasig): Alain U Alisasis, Joanne B Robles; Chong
Hua Hospital (Cebu): Rossini Abbie B Pasanting-Lim, Beatriz C Tan.
Poland: Warsaw University Hospital (Warsaw): Pawel Andruszkiewicz, Karina
Jakubowska;
PORTUGAL: Centro Hospitalar Da Cova Da Beira (Covilhã): Cristina M Coxo;
Hospital Santa Maria, Chln (Lisboa): António M Alvarez, Bruno S Oliveira;
Centro Hospitalar Trás-Os-Montes E Alto Douro - Hospital De S. Pedro -Vila
Real (Vila Real): Gustavo M Montanha, Nelson C Barros; Hospital Beatriz
Ângelo (Loures): Carlos S Pereira, António M Messias; Hospital De Santa Maria
(Lisboa): Jorge M Monteiro; Centro Hospitalar Médio Tejo - Hospital De
Abrantes (Abrantes): Ana M Araujo, Nuno T Catorze; Instituto Português De
Oncologia De Lisboa (Lisboa): Susan M Marum, Maria J Bouw; Hospital Garcia
De Orta (Almada): Rui M Gomes, Vania A Brito; Centro Hospitalar Do Algarve
(Faro): Silvia Castro, Joana M Estilita; Hpp Hospital De Cascais (Alcabideche):
Filipa M Barros; Hospital Prof. Doutor Fernando Fonseca Epe (Amadora):
Isabel M Serra, Aurelia M Martinho.
Romania: Fundeni Clinical Institute (Bucharest): Dana R Tomescu, Alexandra
Marcu; Emergency Clinical County Hospital Timisoara (Timisoara): Ovidiu H
Bedreag, Marius Papurica; Elias University Emergency Hospital (Bucharest):
Dan E Corneci, Silvius Ioan Negoita.
Russian Federation: University Hospital (Kemerovo): Evgeny Grigoriev;
Krasnoyarsk Regional Hospital, Krasnoyarsk State Medical University
(Krasnoyarsk): Alexey I Gritsan, Andrey A Gazenkampf.
Saudi Arabia: GICU of PSMMC (Riyadh): Ghaleb Almekhlafi, Mohamad M
Albarrak; SICU of PSMMC (Riyadh): Ghanem M Mustafa;; King Faisal Hospital And
Research Center (Riyadh): Khalid A Maghrabi, Nawal Salahuddin; King Fahad
Hospital (Baha): Tharwat M Aisa; King Abdulaziz Medical City (Riyadh): Ahmed S
Al Jabbary, Edgardo Tabhan; King Abdulaziz Medical City (Riyadh): Yaseen M
Arabi; King Abdulaziz Medical City (Riyadh): Yaseen M Arabi, Olivia A Trinidad;
King Abdulaziz Medical City (Riyadh): Hasan M Al Dorzi, Edgardo E Tabhan.
South Africa: Charlotte Maxeke Johannesburg Academic Hospital
(Johannesburg): Stefan Bolon, Oliver Smith.
Spain: Hospital Sant Pau (Barcelona): Jordi Mancebo, Hernan Aguirre-Bermeo;
Hospital Universitari Bellvitge (L Hospitalet De Llobregat (Barcelona)): Juan C
Lopez-Delgado, Francisco Esteve; Hospital Son Llatzer (Palma De Mallorca):
Gemma Rialp, Catalina Forteza; Sabadell Hospital, CIBER Enfermedades
Respiratorias (Sabadell): Candelaria De Haro, Antonio Artigas; Hospital
Universitario Central De Asturias (Oviedo): Guillermo M Albaiceta, Sara De
Cima-Iglesias; Complejo Hospitalario Universitario A Coruña (A Coruña):
Leticia Seoane-Quiroga, Alexandra Ceniceros-Barros; Hospital Universitario
Miguel Servet (Zaragoza): Antonio L Ruiz-Aguilar, Luis M Claraco-Vega;
Morales Meseguer University Hospital (Murcia): Juan Alfonso Soler, Maria del
Carmen Lorente; Hospital Universitario del Henares (Coslada): Cecilia
Hermosa, Federico Gordo; Complejo Asistencial De Palencia. Hospital Rio
Carrión (Palencia): Miryam - Prieto-González, Juan B López-Messa; Fundación
Jiménez Díaz (Madrid): Manuel P Perez, Cesar P Perez; Hospital Clínico
Universitario Lozano Blesa (Zaragoza): Raquel Montoiro Allue; Hospital Verge
de la Cinta (Tortosa): Ferran Roche-Campo, Marcos Ibañez-Santacruz; Hospital
Universitario 12 De Octubre (Madrid): Susana - Temprano; Hospital
Universitario Príncipe De Asturias (Alcalá De Henares, Madrid): Maria C
Pintado, Raul De Pablo; Hospital Universitari Germans Trias I Pujol (Badalona):
Pilar Ricart Aroa Gómez; Hospital Universitario Arnau De Vilanova De Lleida
(Lleida): Silvia Rodriguez Ruiz, Silvia Iglesias Moles; Cst Terrassa (Barcelona):
Mª Teresa Jurado, Alfons Arizmendi; Hospital Universitari Mútua Terrassa
(Terrassa): Enrique A Piacentini; Hospital Universitario De Móstoles (Mostoles):
Nieves Franco, Teresa Honrubia; Complejo Asistencial De Salamanca
(Salamanca): Meisy Perez Cheng, Elena Perez Losada; Hospital General
Universitario De Ciudad Real (Ciudad Real): Javier - Blanco, Luis J Yuste;
Torrecardenas (Almeria): Cecilia Carbayo-Gorriz, Francisca G Cazorla-
Barranquero; Hospital Universitario Donostia (San Sebastian): Javier G Alonso,
Rosa S Alda; Hospital Universitario De Torrejón (Madrid): Ángela Algaba,
Gonzalo Navarro; Hospital Universitario De La Princesa (Madrid): Enrique
Cereijo, Esther Diaz-Rodriguez; Hospital Universitario Lucus Augusti (Lugo):
Diego Pastor Marcos, Laura Alvarez Montero; Hospital Universitario Santa
Lucia (Cartagena): Luis Herrera Para, Roberto Jimenez Sanchez; Hospital
Universitario Severo Ochoa, Leganes (Madrid): Miguel Angel Blasco
Navalpotro, Ricardo Diaz Abad; University Hospital Of Ntra. Sra. De Candelaria
(Santa Cruz De Tenerife): Raquel Montiel Gonz á lez, D á cil Parrilla Toribio;
Hospital Universitario Marques De Valdecilla (Santander): Alejandro G Castro,
Maria Jose D Artiga; Hospital Infanta Cristina (Parla, Madrid): Oscar Penuelas;
Hospital General De Catalunya (Sant Cugat Del Valles): Tomas P Roser,
Moreno F Olga; San Pedro De Alcántara (Cáceres): Elena Gallego Curto, Rocío
Manzano Sánchez; Sant Joan De Reus (Reus): Vallverdu P Imma, Garcia M
Elisabet; Hospital Joan XXIII (Tarragona): Laura Claverias, Monica Magret;
Hospital Universitario De Getafe (Madrid): Ana M Pellicer, Lucia L Rodriguez;
Hospital Universitario Río Hortega (Valladolid): Jesús Sánchez-Ballesteros,
Ángela González-Salamanca; Hospital Arquitecto Marcide (Ferrol, La Coruña):
Antonio G Jimenez, Francisco P Huerta; Hospital General Universitario
Gregorio Marañón (Madrid): Juan Carlos J Sotillo Diaz, Esther Bermejo Lopez;
Hospital General De Segovia (Segovia): David D Llinares Moya, Alec A Tallet
Alfonso; Hospital General Universitario Reina Sofia (Murcia): Palazon Sanchez
Eugenio Luis, Palazon Sanchez Cesar; Complejo Hospitalario Universitario De
Albacete (Albacete): Sánchez I Rafael, Corcoles G Virgilio; Hospital Infanta
Elena (Valdemoro): Noelia N Recio.
Sweden: Sahlgrenska University Hospital (Gothenburg): Richard O Adamsson,
Christian C Rylander; Karolinska University Hospital (Stockholm): Bernhard
Holzgraefe, Lars M Broman; Akademiska Sjukhuset Uppsala (Uppsala): Joanna
Wessbergh, Linnea Persson; Vrinnevisjukhuset (Norrköping): Fredrik Schiöler,
Hans Kedelv; Linkoping University Hospital (Linköping): Anna Oscarsson
Tibblin, Henrik Appelberg; Skellefteå Lasarett (Skellefteå): Lars Hedlund, Johan
Helleberg; Karolinska University Hospital Solna (Stockholm): Karin E Eriksson,
Rita Glietsch; Umeå University Hospital (Umeå): Niklas Larsson, Ingela Nygren;
Danderyd Hospital (Stockholm): Silvia L Nunes, Anna-Karin Morin; Lund
University Hospital (Lund): Thomas Kander, Anne Adolfsson.
Switzerland: Chuv (Centre Hospitalier Universitaire Vaudois) (Lausanne): Lise
Piquilloud; Hôpital neuchâtelois - La Chaux-De-Fonds (La Chaux-De-Fonds):
Hervé O. Zender, Corinne Leemann-Refondini.
Tunisia: Hopital Taher Sfar Mahdia (Mahdia): Souheil Elatrous; University
Hospital Farhat Hached Sousse (Sousse): Slaheddine Bouchoucha, Imed
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Chouchene; CHU F Bourguiba (Monastir): Islem Ouanes; Mongi Slim
University Hospital, La Marsa (La Marsa): Asma Ben Souissi, Salma Kamoun;
TURKEY: Cerrahpasa Medical Faculty Emergency Intensive Care Unit
(Istanbul): Oktay Demirkiran; Cerrahpasa Medical Faculty Sadi Sun Intensive
Care Unit (Istanbul): Mustafa Aker, Emre Erbabacan; Uludag University
Medical Faculty (Bursa): Ilkay Ceylan, Nermin Kelebek Girgin; Ankara
University Faculty of Medicine, Reanimation 3nd level ICU (Ankara): Menekse
Ozcelik, Necmettin Ünal; Ankara University Faculty of Medicine, 2nd level
ICU-postoperative ICU (Ankara): Basak Ceyda Meco; Istanbul Kartal Egitim Ve
Arastirma Hastanesi (Istanbul): Onat O Akyol, Suleyman S Derman.
United Kingdom: Papworth Hospital (Cambridge): Barry Kennedy, Ken Parhar;
Royal Glamorgan Hospital (Llantrisant): Latha Srinivasa; Royal Victoria
Hospital-Belfast (Belfast): Lia McNamee, Danny McAuley; Jack Steinberg ICU
of the King’s College (London): Phil Hopkins, Clare Mellis; Frank Stansil ICU of
the King’s College Hospital (London): Vivek Kakar; Liver ICU of the King’s
College (London): Dan Hadfield; Christine Brown ICU of the King’s College
(London): Andre Vercueil; West Suffolk Hospital (Bury St Edmunds): Kaushik
Bhowmick, Sally K Humphreys; Craigavon Area Hospital (Portadown): Andrew
Ferguson, Raymond Mckee; Barts Health NHS Trust, Whipps Cross Hospital
(Leytonstone): Ashok S Raj, Danielle A Fawkes; Kettering General Hospital,
Foundation NHS Trust (Northamptonshire): Philip Watt, Linda Twohey; Barnet
General Hospital (Barnet): Rajeev R JhaMatthew Thomas, Alex Morton, Varsha
Kadaba; Rotherham General Hospital (Rotherham): Mark J Smith, Anil P
Hormis; City Hospital, (Birmingham): Santhana G Kannan, Miriam Namih;
Poole Hospital NHS Foundation Trust (Poole): Henrik Reschreiter, Julie
Camsooksai; Weston General Hospital (Weston-Super-Mare): Alek Kumar,
Szabolcs Rugonfalvi; Antrim Area Hospital (Antrim): Christopher Nutt, Orla
Oneill; Aintree University Hospital (Liverpool): Colette Seasman, Ged
Dempsey; Northern General Hospital (Sheffield): Christopher J Scott, Helen E
Ellis; John Radcliffe Hospital (Oxford): Stuart Mckechnie, Paula J Hutton; St
Georges Hospital (London): Nora N Di Tomasso, Michela N Vitale; Hillingdon
Hospital (Uxbridge): Ruth 0 Griffin, Michael N Dean; The Royal Bournemouth
& Christchurch NHS Foundation Trust (Bournemouth, Dorset): Julius H
Cranshaw, Emma L Willett; Guys And St Thomas NHS Foundation Trust
(London): Nicholas Ioannou, Gstt Severe Respiratory Failure Service;
Whittington Hospital (London): Sarah Gillis; Wexham Park Hospital (Slough):
Peter Csabi; Western General Hospital (Edinburgh): Rosaleen Macfadyen,
Heidi Dawson; Royal Preston Hospital (Preston): Pieter D Preez, Alexandra J
Williams; Brighton And Sussex University Hospitals NHS Trust (Brighton):
Owen Boyd, Laura Ortiz-Ruiz De Gordoa; East And North Herts NHS Trust
(Stevenage): Jon Bramall, Sophie Symmonds; Barnsley Hospital (Barnsley):
Simon K Chau, Tim Wenham; Prince Charles Hospital (Merthyr Tydfil): Tamas
Szakmany, Piroska Toth-Tarsoly; University Hospital Of South Manchester NHS
Foundation Trust (Manchester): Katie H Mccalman, Peter Alexander;
Harrogate District Hospital (Harrogate): Lorraine Stephenson, Thomas Collyer;
East And North Herts NHS Trust (Welwyn Garden City): Rhiannon Chapman,
Raphael Cooper; Western Infirmary (Glasgow): Russell M Allan, Malcolm Sim;
Dumfries And Galloway Royal Infirmary (Dumfries): David W Wrathall, Donald
A Irvine; Charing Cross Hospital (London): Kim S Zantua, John C Adams;
Worcestershire Royal Hospital (Worcester): Andrew J Burtenshaw, Gareth P
Sellors; Royal Liverpool University Hospital (Liverpool): Ingeborg D Welters,
Karen E Williams; Royal Alexandra Hospital (Glasgow): Robert J Hessell,
Matthew G Oldroyd; Morriston Hospital (Swansea): Ceri E Battle, Suresh Pillai;
Frimley Park Hospital (Frimley): Istvan - Kajtor, Mageswaran -
Sivashanmugavel; Altnagelvin Hospital (Derry): Sinead C Okane, Adrian
Donnelly; Buckinghamshire Healthcare NHS Trust (High Wycombe,
Buckinghamshire): Aniko D Frigyik, Jon P Careless; Milton Keynes Hospital
(Milton Keynes): Martin M May, Richard Stewart; Ulster Hospital (Belfast): T
John Trinder, Samantha J Hagan; University Hospital of Wales (Cardiff): Matt P
Wise, Jade M Cole; Freeman Hospital (Newcastle Upon Tyne): Caroline C
MacFie, Anna T Dowling.
Uruguay: Hospital Español (Montevideo): Javier Hurtado, Nicolás Nin; Cudam
(Montevideo): Javier Hurtado; Sanatorio Mautone (Maldonado): Edgardo
Nuñez; Sanatorio Americano (Montevideo): Gustavo Pittini, Ruben Rodriguez;
Hospital De Clínicas (Montevideo): María C Imperio, Cristina Santos; Circulo
Católico Obreros Uruguay- Sanatorio JPII (Montevido: Ana G. França,
Alejandro EBEID; CASMU (Montevideo): Alberto Deicas, Carolina Serra.
USA: Saint Louis University Hospital (St Louis): Aditya Uppalapati, Ghassan
Kamel; Beth Israel Deaconess Medical Center (Boston): Valerie M Banner-
Goodspeed, Jeremy R Beitler; Memorial Medical Center (Springfield):
Satyanarayana Reddy Mukkera, Shreedhar Kulkarni; Massachusetts General
Hospital (Boston): Jarone Lee, Tomaz Mesar; University Of Cincinnati Medical
Center (Cincinnati): John O Shinn Iii, Dina - Gomaa; Massachusetts General
Hospital (Boston): Christopher Tainter, Jarone Lee; Massachusetts General
Hospital (Boston): Tomaz Mesar, Jarone Lee; R Adams Cowley Shock Trauma
Center (Baltimore): Dale J Yeatts, Jessica Warren; Intermountain Medical
Center (Murray, Utah): Michael J Lanspa, Russel R Miller; Intermountain
Medical Center (Murray, Utah): Colin K Grissom, Samuel M Brown; Mayo
Clinic (Rochester): Philippe R Bauer; North Shore Medical Center (Salem):
Ryan J Gosselin, Barrett T Kitch; Albany Medical Center (Albany): Jason E
Cohen, Scott H Beegle; John H Stoger Hospital Of Cook County (Chicago, Il):
Renaud M Gueret, Aiman Tulaimat; Albany Medical Center (Albany): Shazia
Choudry; University of Alabama at Birmingham (UAb) (Birmingham, AL):
William Stigler, Hitesh Batra; Duke University Hospital (Durham): Nidhi G Huff;
Iowa Methodist Medical Center (Des Moines, Iowa): Keith D Lamb, Trevor W
Oetting; Surgical & Neurosciences Intensive Care Unit of the University Of
Iowa Hospitals And Clinics (Iowa City, Iowa): Nicholas M Mohr, Claine Judy;
Medical Center of Louisiana at New Orleans (New Orleans, Louisiana): Shigeki
Saito, Fayez M Kheir; Tulane University (New Orleans): Fayez Kheir; Critical
Care Unit of the University Of Iowa Hospitals And Clinics (Iowa City, Iowa):
Adam B Schlichting, Angela Delsing; University Of California, San Diego
Medical Center (San Diego, CA): Daniel R Crouch, Mary Elmasri; Uc San Diego
Thornton Hospital (La Jolla): Daniel R Crouch, Dina Ismail; University Hospital
(Cincinnati): Kyle R Dreyer, Thomas C Blakeman; University Hospital
(Cincinnati): Kyle R Dreyer, Dina Gomaa; Tower 3B Medical ICU of Brigham
and Women’s Hospital (Boston): Rebecca M Baron, Carolina Quintana
Grijalba; Tower 8C Burn/Trauma ICU of Brigham and Women’s Hospital
(Boston): Peter C Hou; Tower 8D Surgical ICU of Brigham and Women’s
Hospital (Boston): Raghu Seethala; Tower 9C Neurosurgical ICU of Brigham
and Women’s Hospital (Boston): Imo Aisiku; Tower 9D Neurological ICU of
Brigham and Women’s Hospital (Boston): Galen Henderson; Tower 11C
Thoracic ICU of Brigham and Women’s Hospital (Boston): Gyorgy Frendl;
Shapiro 6 W Cardiac Surgery ICU of Brigham and Women’s Hospital (Boston):
Sen-Kuang Hou; Shapiro 9E Coronary Care Unit of Brigham and Women’s
Hospital (Boston): Robert L Owens, Ashley Schomer.
Serbia: Clinical Center of Serbia (Belgrade): Vesna Bumbasirevic, Bojan
Jovanovic; Military Medical Academy (Belgrade): Maja Surbatovic, Milic
Veljovic.
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